AOD 9604 Research Peptide

AOD 9604 — USA Made, ≥99% Purity

4.9 177 verified reviews

USA manufactured in GMP-certified laboratory facilities in California and Arizona
≥99% purity target with third-party HPLC and mass spectrometry verification
Freeze-dried 5mg vial with one combined, batch-specific COA report

Vial Size

Manufactured in a GMP facility · Independently tested · Batch COA

Dispatched from a US warehouse within 48 hours, tracked

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Specifications

Purity target

≥99%

≥99% (3rd-Party HPLC Tested)

Molecular mass

1,815.1

g/mol, confirmed by mass spectrometry

Vial content

5 MG

Lyophilized Powder

Sequences

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe; Cys7–Cys14 disulfide bridge

CAS: 221231-10-3
Molecular mass: 1,815.1 g/mol
Purity target: ≥99% (3rd-Party HPLC Tested)
Form: Lyophilized Powder
Origin: Manufactured, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is AOD 9604?

AOD 9604 is a synthetic, 16-amino-acid research peptide modeled on the C-terminal region of human growth hormone. Its compact structure lets researchers isolate this specific peptide region without working with the entire 191-amino-acid hormone.

Laboratory studies have examined AOD 9604 in models of lipid metabolism, including how cells break down and form stored lipids. Most mechanistic findings are preclinical, so this material is intended for controlled non-clinical research rather than personal use.

How It Works

Isolates a defined peptide signal: AOD 9604 reproduces a short C-terminal growth hormone sequence for focused experimental study.

Modulates lipid pathways in research models: Cell and animal studies have reported changes in lipolysis and lipogenesis signaling.

Appears linked to beta-3 adrenergic signaling: Animal work points to increased beta-3 receptor expression and pathway dependence, although a definitive direct molecular target has not been established.

Why Source from 321 Peptides?

Domestic accountability.

AOD 9604 is synthesized and finished in GMP-certified laboratory facilities in California and Arizona—never sourced from overseas or Mexico. That creates a shorter, more accountable supply chain from production to order fulfillment.

Verification you can inspect.

Every batch targets ≥99% purity and is evaluated through independent third-party HPLC, while mass spectrometry checks molecular identity. Both results are documented in one batch-specific COA report.

Protected in transit.

Freeze-drying helps preserve compound stability during storage and shipping. Rapid domestic fulfillment reduces unnecessary time in the delivery network.

Lot history 6 released lots

Every batch released under this compound, with the figure reported for each.

Lot	Reported	Purity	Net content	COA
AO-58700 Superseded	2026-05-12	99.52%	5.04 mg	Pending
AO-57546 Superseded	2026-05-06	99.88%	5.03 mg	Pending
AO-58123 Superseded	2026-05-02	99.71%	5.03 mg	Pending
AO-35679 Superseded	2026-04-23	99.64%	10.00 mg	Pending
AO-36256 Superseded	2026-03-19	99.88%	10.01 mg	Pending
AO-35102 Superseded	2026-02-25	99.52%	10.08 mg	Pending

Frequently Asked Questions

What is AOD 9604 peptide?

AOD 9604 is a synthetic 16-amino-acid peptide modeled on the C-terminal region of human growth hormone. It is studied in non-clinical laboratory models involving lipid metabolism.

How does AOD 9604 work?

Preclinical research suggests AOD 9604 affects signals associated with lipid breakdown, lipid formation, and beta-3 adrenergic receptor expression. Its exact direct molecular target has not been conclusively established.